ObsEva SA: ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
May
4
, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced that it has completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty for patients with moderate to severe endometriosis-associated pain (EAP). Enrollment completion is an important milestone, and data from the primary endpoint readout are expected in Q4 2021. Endometriosis is an emotionally and physically painful condition that affects approximately 176 million women worldwide and can be debilitating for many women. We continue to be in need of alternative treatment options that improve quality of life, said Jacques Donnez, M.D., Ph.D., Distinguished Professor of Obstetrics and Gynecology at the Catholic University of Louvain, Belgium.
Semtech and EchoStar Mobile to Test Satellite IoT Connectivity Service Integrated With LoRaWAN® – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
RICHMOND, Va., May 4, 2021 /PRNewswire/ Genworth Mortgage Holdings, Inc. (GMHI) today announced that it has commenced an initial public offering of 22,576,140 shares of common stock. All of the shares are being offered by the selling stockholder, Genworth Holdings, Inc. (GHI), a wholly owned subsidiary of Genworth Financial, Inc., and net proceeds from the offering will go to GHI.
In connection with the commencement of the initial public offering, GMHI has announced that it will rebrand, changing its name to Enact Holdings, Inc. (Enact).
The initial public offering price is expected to be between $20.00 and $24.00 per share. GHI expects to grant the underwriters a 30-day option to purchase up to an additional 3,386,420 shares of Enact s common stock at the initial public offering price, less the underwriting discount. The shares are expected to trade on the Nasdaq Global Select Market under the ticker symbol ACT.